GlaxoSmithKline, Sanofi Join Forces to Develop Coronavirus Vaccine
14 Abril 2020 - 06:29AM
Noticias Dow Jones
By Ian Walker
GlaxoSmithKline PLC and Sanofi SA said Tuesday that they have
signed a preliminary agreement to develop an adjuvanted vaccine for
the new coronavirus, or Covid-19.
The pharmaceutical giants said they hope to start Phase 1
clinical trails in the second half of this year, and if approved by
regulators expect the vaccine to be available by the second half of
2021.
"This collaboration brings two of the world's largest vaccines
companies together. By combining our science and our technologies,
we believe we can help accelerate the global effort to develop a
vaccine to protect as many people as possible from Covid-19," Glaxo
Chief Executive Emma Walmsley said.
Sanofi Chief Executive Paul Hudson said the goal is to create
and supply sufficient quantities of vaccines that will help stop
the virus.
"As the world faces this unprecedented global health crisis, it
is clear that no one company can go it alone," Mr. Hudson said.
An adjuvant is added to some vaccines to enhance the immune
response, and has been shown to create a stronger and longer
lasting immunity against infections than the vaccine alone. It can
also improve the likelihood of delivering an effective vaccine that
can be manufactured at scale.
Write to Ian Walker at ian.walker@wsj.com; @IanWalk40289749
(END) Dow Jones Newswires
April 14, 2020 07:14 ET (11:14 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
Gsk (LSE:GSK)
Gráfica de Acción Histórica
De Feb 2024 a Mar 2024
Gsk (LSE:GSK)
Gráfica de Acción Histórica
De Mar 2023 a Mar 2024